Jesse Joachim Swen (Jesse J Swen)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 64

Top Venues

Clinical pharmacology and therapeutics

Genes

European journal of human genetics : EJHG

Clinical and translational science

Leiden University Medical Center

Leiden University Medical Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Leiden University Medical Center Oct 01 2016

Netherlands

Chair of the Laboratory for TDM, Quality Control and Pharmacogenomics :: Clinical Pharmacy and Toxicology

Leiden University Medical Center May 01 2015

Netherlands

Associate Professor of Pharmacogenetics :: Clinical Pharmacy and Toxicology

Leiden University Medical Center Feb 01 2012 - Apr 01 2015

Netherlands

Assistant Professor of Pharmacogenetics :: Clinical Pharmacy and Toxicology

Stanford University

United States

Visiting Researcher :: Genetics / PharmGKb

Education History

Leiden University Medical Center

Netherlands

PHD :: Clinical Pharmacy and Toxicology

Publications

Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics (2024)
Anabel Beatriz Sanchez-Spitman, Stefan Böhringer, Vincent Olaf Dezentjé, André B P van Kuilenburg, Jesse Joachim Swen, Henk-Jan Guchelaar
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients. Clinical pharmacology and therapeutics 116 (1) (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics (2024)
Eline L Giraud, Stefanie D Krens, Stefan Böhringer, Ingrid M E Desar, Sita H Vermeulen, Lambertus A Kiemeney, Alwin D R Huitema, Neeltje Steeghs, Nielka P van Erp, Jesse Joachim Swen
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. British journal of clinical pharmacology (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European journal of human genetics : EJHG (2024)
Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics 115 (6) (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European journal of human genetics : EJHG 32 (8) (2024)
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European journal of human genetics : EJHG 32 (8) (2024)
Anabel Beatriz Sanchez-Spitman, Stefan Böhringer, Vincent Olaf Dezentjé, André B P van Kuilenburg, Jesse Joachim Swen, Henk-Jan Guchelaar
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients. Clinical pharmacology and therapeutics (2024)
Lianne Beunk, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Henk-Jan Guchelaar, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Vera H M Deneer, Roos van Westrhenen
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants. European journal of human genetics : EJHG (2024)
Eleonora Camilleri, Mira Ghobreyal, Mettine H A Bos, Pieter H Reitsma, Felix J M Van Der Meer, Jesse Joachim Swen, Suzanne C Cannegieter, Nienke van Rein
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Pharmacotherapy (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics 116 (3) (2024)
Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Eleonora Camilleri, Mira Ghobreyal, Mettine H A Bos, Pieter H Reitsma, Felix J M Van Der Meer, Jesse Joachim Swen, Suzanne C Cannegieter, Nienke van Rein
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Pharmacotherapy 44 (6) (2024)
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European journal of human genetics : EJHG 32 (8) (2024)
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European journal of human genetics : EJHG 32 (8) (2024)
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C M de Winter, Jesse Joachim Swen, Paul P H Le Brun, Erica C M Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A R Moes, Kirsten J M Schimmel
Development and bioequivalence of 3D-printed medication at the point-of-care: bridging the gap towards personalized medicine. Clinical pharmacology and therapeutics (2023)
Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron H J Mathijssen, André B P van Kuilenburg, Henk-Jan Guchelaar, Jesse Joachim Swen
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety. Pharmacogenomics (2023)
Marleen Elizabeth Jansen, Tessel Rigter, Thom M C Fleur, Patrick C Souverein, W M Monique Verschuren, Susanne J Vijverberg, Jesse Joachim Swen, Wendy Rodenburg, Martina Cornelia Cornel
Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. Genes 14 (2) (2023)
Marleen Elizabeth Jansen, Tessel Rigter, Thom M C Fleur, Patrick C Souverein, W M Monique Verschuren, Susanne J Vijverberg, Jesse Joachim Swen, Wendy Rodenburg, Martina Cornelia Cornel
Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. Genes 14 (2) (2023)
Amar D Levens, Melina C den Haan, Johan Wouter Jukema, Mette Heringa, Wilbert B van den Hout, Dirk Jan A R Moes, Jesse Joachim Swen
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes 14 (3) (2023)
Emma C Hulshof, Maarten J Deenen, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Daniel J Touw, Jan van der Weide, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar, Jesse Joachim Swen
Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG (2023)
Chang Yue Chui, Dirk Jan A R Moes, Stijn L W Koolen, Jesse Joachim Swen, Hans Gelderblom
Pharmacokinetic Profile of Irinotecan in Patients with Chronic Kidney Disease: Two Cases and Literature Review. British journal of clinical pharmacology (2023)
Amar D Levens, Melina C den Haan, Johan Wouter Jukema, Mette Heringa, Wilbert B van den Hout, Dirk Jan A R Moes, Jesse Joachim Swen
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes 14 (3) (2023)
Elena Peruzzi, Rossana Roncato, Elena De Mattia, Alessia Bignucolo, Jesse Joachim Swen, Henk-Jan Guchelaar, Giuseppe Toffoli, Erika Cecchin
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? British journal of clinical pharmacology (2023)
Lianne Beunk, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Henk Jan Guchelaar, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Roos van Westrhenen, Vera H M Deneer, Jan van der Weide
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. European journal of human genetics : EJHG (2023)
Ron H N van Schaik, Vangelis G Manolopoulos, Ann K Daly, Mikko Niemi, Branka Zukic, George P Patrinos, Dragan Primorac, Jesse Joachim Swen, Magnus Ingelman-Sundberg, Tiffany Morris, Espen Molden, Daniel Müller, Sonja Pavlovic, Stefan Russmann, Marc Ansari, Linda M Henricks, Wout van den Broek, Francesco Florindi, Nada Bozina, Demet Akin, Lona Christrup, Adrián LLerena, Cilla Sipeky, Sanja Stankovic
The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress (Belgrade, 8-9 November 2022). Pharmacogenomics (2023)
Marleen Elizabeth Jansen, Tessel Rigter, Thom M C Fleur, Patrick C Souverein, W M Monique Verschuren, Susanne J Vijverberg, Jesse Joachim Swen, Wendy Rodenburg, Martina Cornelia Cornel
Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. Genes 14 (2) (2023)
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C M de Winter, Jesse Joachim Swen, Paul P H Le Brun, Erica C M Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A R Moes, Kirsten J M Schimmel
Development and Bioequivalence of 3D-Printed Medication at the Point-of-Care: Bridging the Gap Toward Personalized Medicine. Clinical pharmacology and therapeutics (2023)
Nadia de Gruil, Stefan Böhringer, Stefanie de Groot, Hanno Pijl, Judith R Kroep, Jesse Joachim Swen
IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial). Cancers 15 (24) (2023)
Stephanie Feleus, Maaike van der Lee, Jesse Joachim Swen, Raymund A C Roos, Susanne T de Bot
Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington's disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics. Therapeutic advances in rare disease 4 (2023)
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier M Meulendijks, Peter Nieboer, Helga J Droogendijk, Geert-Jan M Creemers, Caroline M P W Mandigers, Alexander L T Imholz, Ron H J Mathijssen, Johanneke E A Portielje, Liselot Valkenburg-van Iersel, Annelie Vulink, Marlene H W van der Poel, Arnold Baars, Jesse Joachim Swen, André B P van Kuilenburg, Jan H M Schellens, Jos H Beijnen, Henk-Jan Guchelaar, Annemieke Cats
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients. Clinical pharmacology and therapeutics (2023)
Nadia de Gruil, Stefan Böhringer, Stefanie de Groot, Hanno Pijl, Judith R Kroep, Jesse Joachim Swen
IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial). Cancers 15 (24) (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics (2023)
Amar D Levens, Melina C den Haan, Johan Wouter Jukema, Mette Heringa, Wilbert B van den Hout, Dirk Jan A R Moes, Jesse Joachim Swen
Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes 14 (3) (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics 113 (4) (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics 113 (4) (2023)
Karel H van der Pol, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne Marie Buunk, Henk-Jan Guchelaar, Arne Risselada, Ron H N van Schaik, Jesse Joachim Swen, Daan Touw, Jan van der Weide, Roos van Westrhenen, Vera H M Deneer, Elisa J F Houwink, Gerard A Rongen
Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate. European journal of human genetics : EJHG (2022)
Maaike van der Lee, Jesse Joachim Swen
Artificial intelligence in pharmacology research and practice. Clinical and translational science (2022)
Meta H M Diekstra, Jesse Joachim Swen, Loes F M van der Zanden, Sita H Vermeulen, Epie Boven, Ron H J Mathijssen, Koya Fukunaga, Taisei Mushiroda, Fumiya Hongo, Egbert Oosterwijk, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Cristina Rodriguez-Antona, Rob Ruijtenbeek, Marius T Radu, Tim Eisen, Kerstin Junker, Max Roessler, Ulrich Jaehde, Tsuneharu Miki, Stefan Böhringer, Michiaki Kubo, Lambertus A L M Kiemeney, Henk-Jan Guchelaar
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers 14 (12) (2022)
Alireza Tafazoli, Maaike van der Lee, Jesse Joachim Swen, Anna Zeller, Natalia Wawrusiewicz-Kurylonek, Hailiang Mei, Ruben H P Vorderman, Krzysztof Konopko, Andrzej Zankiewicz, Wojciech Miltyk
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data. The pharmacogenomics journal 22 (5-6) (2022)
Mirjam de With, Jonathan E Knikman, Jan H M Schellens, André B P van Kuilenburg, Annemieke Cats, Henk-Jan Guchelaar, Ron H J Mathijssen, Jesse Joachim Swen, Didier Meulendijks
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters". Clinical pharmacology and therapeutics (2022)
Marga Nijenhuis, Bianca Soree, Wafa O M Jama, Nienke J de Boer-Veger, Anne Marie Buunk, Henk-Jan Guchelaar, Elisa J F Houwink, Gerard A Rongen, Ron H N van Schaik, Jesse Joachim Swen, Daniel J Touw, Jan van der Weide, Roos van Westrhenen, Vera H M Deneer, Arne Risselada
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate. European journal of human genetics : EJHG (2022)
Emma C Hulshof, Maarten J Deenen, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Daniel J Touw, Jan van der Weide, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar, Jesse Joachim Swen
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG (2022)
Laura M de Jong, Sylvia D Klomp, Nicoline Treijtel, Robert Rissmann, Jesse Joachim Swen, Martijn L Manson
A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling. British journal of clinical pharmacology 88 (10) (2022)
Stuart A Scott, Jesse Joachim Swen
Pharmacogenomic Determinants of Interindividual Drug Response Variability: From Discovery to Implementation. Genes 12 (3) (2021)
Maaike van der Lee, William G Allard, Rolf H A M Vossen, Renée F Baak-Pablo, Roberta Menafra, Birgit A L M Deiman, Maarten J Deenen, Patrick Neven, Inger Johansson, Stefano Gastaldello, Magnus Ingelman-Sundberg, Henk-Jan Guchelaar, Jesse Joachim Swen, Seyed Yahya Anvar
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Science translational medicine 13 (603) (2021)
Jurriaan M J L Brouwer, Marga Nijenhuis, Bianca Soree, Henk-Jan Guchelaar, Jesse Joachim Swen, Ron H N van Schaik, Jan van der Weide, Gerard A P J M Rongen, Anne-Marie Buunk, Nienke J de Boer-Veger, Elisa J F Houwink, Roos van Westrhenen, Bob Wilffert, Vera H M Deneer, Hans Mulder
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European journal of human genetics : EJHG (2021)
Maaike van der Lee, William J Rowell, Roberta Menafra, Henk-Jan Guchelaar, Jesse Joachim Swen, Seyed Yahya Anvar
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. The pharmacogenomics journal (2021)
Maaike van der Lee, Henk-Jan Guchelaar, Jesse Joachim Swen
Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics 22 (16) (2021)
Laura M de Jong, Wim Jiskoot, Jesse Joachim Swen, Martijn L Manson
Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. Genes 11 (12) (2020)
Rick Overkleeft, Judith Tommel, Andrea W M Evers, Johan T den Dunnen, Marco Roos, Marie-José Hoefmans, Walter E Schrader, Jesse Joachim Swen, Mattijs E Numans, Elisa J F Houwink
Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics. Genes 11 (12) (2020)
Maaike van der Lee, Marjolein Kriek, Henk-Jan Guchelaar, Jesse Joachim Swen
Technologies for Pharmacogenomics: A Review. Genes 11 (12) (2020)
Sylvia D Klomp, Martijn L Manson, Henk-Jan Guchelaar, Jesse Joachim Swen
Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of clinical medicine 9 (9) (2020)
Cathelijne H van der Wouden, Ellen Paasman, Martina Teichert, Matty R Crone, Henk-Jan Guchelaar, Jesse Joachim Swen
Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. Journal of clinical medicine 9 (3) (2020)
Teun van Gelder, Oumaima Etsouli, Dirk Jan A R Moes, Jesse Joachim Swen
Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes 11 (10) (2020)
Cathelijne H van der Wouden, Mandy H van Rhenen, Wafa O M Jama, Magnus Ingelman-Sundberg, Volker Martin Lauschke, Lidija Konta, Matthias Schwab, Jesse Joachim Swen, Henk-Jan Guchelaar
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. Clinical pharmacology and therapeutics 106 (4) (2019)
Cathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, Jesse Joachim Swen, Henk-Jan Guchelaar
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. Genes 10 (6) (2019)
Maaike van der Lee, William G Allard, Sander Bollen, Gijs W E Santen, Claudia A L Ruivenkamp, Mariëtte J V Hoffer, Marjolein Kriek, Henk-Jan Guchelaar, Seyed Y Anvar, Jesse Joachim Swen
Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. Clinical pharmacology and therapeutics 107 (3) (2019)

Jesse Joachim Swen.css-eqlu8i{font-size:small;padding-left:4px;} (Jesse J Swen)

Publication Activity (10 Years)

Top Topics

Top Venues

Jesse Joachim Swen (Jesse J Swen)